Reported about 7 hours ago
Johnson & Johnson (JNJ) surpassed analyst expectations in its fourth quarter earnings report. Nonetheless, the company faces ongoing challenges, including foreign exchange difficulties, declining medical device sales in China, and potential competition from generic versions of its drug Stelara.
Source: YAHOO